Hepatic venoocclusive disease

: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92 (2): 406-13, 2001.
Karp JE, Lancet JE, Kaufmann SH, et al.

familial veno-occlusive disease with immunodeficiency
hepatic venoocclusive disease with immunodeficiency
veno-occlusive disease and immunodeficiency syndrome
See How are genetic conditions and genes named? in the Handbook.

See also: Genetics, Deficiency, Infections, Fibrosis, Symptom